Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:32 p.m.

    📋 Landos Biopharma, Inc. (LABP) - Clinical Trial Update

    Filing Date: 2022-08-03

    Accepted: 2022-08-03 08:30:57

    Event Type: Clinical Trial Update

    Event Details:

    Landos Biopharma Inc (was acquired by AbbVie Inc. (NYSE: ABBV) on 25/03/2024) (LABP) Announces Clinical Trial Update Landos Biopharma Inc (was acquired by AbbVie Inc. (NYSE: ABBV) on 25/03/2024) (LABP) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: milestone, medicines
    • Diseases/Conditions: Ulcerative Colitis Planned NEW YORK, efficacy
    • Clinical Stage: Clinical Trial, Phase 2
    • Collaboration: Landos Biopharma, Inc.

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Landos Biopharma Inc (was acquired by AbbVie Inc. (NYSE: ABBV) on 25/03/2024)
    • CIK: 0001785345
    • Ticker Symbol: LABP
    • Period End Date: 2022-08-03
    • Document Type: 8-K

Search

News categories